Skip to main content

Table 2 Clinical Characteristics and Therapeutic Efficacy in Patients with Newly Diagnosed Adult NKTCL (n = 33)

From: PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity

Characteristic Patients (%) CR (%) NO CR (%) p value
Age
 <60 years 30 (90.9) 23 (76.7) 7 (23.3) 1.000
 ≥ 60 years 3 (9.1) 2 (66.7) 1 (33.3)  
Gender
 Male 19 (57.6) 16 (84.2) 3 (15.8) 0.238
 Female 14 (42.2) 9 (64.3) 5 (35.7)  
Primary site
 UNKTCL 30 (90.9) 23 (76.7) 7 (23.3) 1.000
 EUNKTCL 3 (9.1) 2 (66.7) 1 (33.3)  
An Arbor Stage
 I~II 21 (63.6) 19 (90.5) 2 (9.5) 0.015*
 III~IV 12 (36.4) 6 (50.0) 6 (50.0)  
B symptom
 Yes 12 (36.4) 9 (75.0) 3 (25.0) 1.000
 No 21 (63.6) 16 (76.2) 5 (23.8)  
ECOG
 0–1 27 (81.8) 21 (77.8) 6 (22.2) 0.616
 ≥ 2 6 (18.2) 4 (66.7) 2 (33.3)  
LDH
 Increased 7 (21.2) 2 (28.6) 5 (71.4) 0.004*
 Normal 26 (78.8) 23 (88.5) 3 (11.5)  
IPI score
 0~ 1 22 (66.7) 21 (95.5) 1 (4.5) < 0.001*
 ≥ 2 11 (33.3) 4 (36.4) 7 (63.6)  
β2-microglobulin
 Increased 8 (24.2) 5 (62.5) 3 (37.5) 0.366
 Normal 25 (75.8) 20 (80.0) 5 (20.0)  
BM involvement
 Yes 4 (12.1) 3 (75.0) 1 (25.0) 1.000
 No 29 (87.9) 22 (75.9) 7 (24.1)  
Lymph node involvement
 Yes 12 (36.4) 9 (75.0) 3 (25.0) 1.000
 No 21 (63.6) 16 (76.2) 5 (23.8)  
Extranodal involvement site
 0–1 26 (78.8) 22 (84.6) 4 (15.4) 0.042
 ≥ 2 7 (21.2) 3 (42.9) 4 (57.1)  
Allergy history
 Yes 1 (3.0) 0 (0.0) 1 (100.0) 0.242
 No 32 (97.0) 25 (78.1) 7 (21.9)  
  1. Abbreviations: CR complete remission, No CR included PR partial remission, SD stable disease and PD progressive disease
  2. *Fisher’s exact test, sample sizes in some cells are 5 or less